Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 10/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891859 | 0.94 | HDAC4 (0.39) | HDAC4HDAC6GPR119HDAC1MAPK1 | |
| SCHEMBL2906289 | 0.92 | HDAC4 (0.37) | HDAC4HDAC6GPR119ACACBSYK | |
| SCHEMBL2894005 | 0.90 | MTOR (0.40) | HDAC4HDAC6GPR119HDAC1ACACB | |
| SCHEMBL13024281 | 0.89 | GPR119 (0.39) | GPR119 | |
| SCHEMBL2904085 | 0.88 | GRM2 (0.40) | GPR119MAPK1 | |
| SCHEMBL2893546 | 0.88 | GPR119 (0.38) | GPR119 | |
| SCHEMBL2893540 | 0.88 | GPR119 (0.38) | GPR119ACACB | |
| SCHEMBL2893913 | 0.86 | GPR119 (0.35) | GPR119ACACBMAPK1 | |
| SCHEMBL2891626 | 0.86 | GPR119 (0.38) | GPR119ACACBMAPK1 | |
| SCHEMBL3663119 | 0.86 | GPR119 (0.37) | GPR119ACACBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009050523-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | GPR119, GIPR, GPR39 | HDAC4 4352/4885HDAC6 4057/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.